1245708-05-7

Upstream product

• 701232-66-8 [4-(4-hydroxyphenyl)cyclohexylidene]acetic acid methyl ester 
• 105640-07-1 4-(4-hydroxyphenyl)cyclohexan-1-one 

Downstream Products

• 1372157-86-2 methyl 2-(4-(4-(((trifluoromethyl)sulfonyl)oxy)phenyl)cyclohexyl)acetate 
• 1245708-73-9 2-((1r,4r)-4-(4-(1-(phenylcarbamoyl)-1H-indol-5-yl)phenyl)cyclohexyl)acetic acid 
• 1245708-75-1 2-((1r,4r)-4-(4-(4-(phenylcarbamoyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl) phenyl) cyclohexyl)acetic acid 
• 701232-67-9 trans-[4-(4-hydroxyphenyl)cyclohexyl]acetic methyl ester 
• 1245708-07-9 methyl 2-((1s,4s)-4-(4-hydroxyphenyl)cyclohexyl)acetate 
• 701232-68-0 (trans)-methyl 2-(4-(4-(((trifluoromethyl)sulfonyl)oxy)phenyl)cyclohexyl)acetate 
• 701232-69-1 methyl 2-((trans)-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)cyclohexyl)acetate 
• 1245708-06-8 methyl 2-((1s,4s)-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)cyclohexyl)acetate 
• 1245708-08-0 4-((1r,4r)-4-(2-methoxy-2-oxoethyl)cyclohexyl)phenylboronic acid 
• 1245708-77-3 2-((1r,4r)-4-(4-(4-(phenylcarbamoyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)phenyl) cyclohexyl)acetic acid 
• 1245708-78-4 2-((1r,4r)-4-(4-(4-(phenylcarbamoyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)phenyl)cyclohexyl)acetic acid 
• 1245708-80-8 2-((1r,4r)-4-(4-(4-(phenylcarbamoyl)-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-7-yl)phenyl)cyclohexyl)acetic acid 
• 1245708-23-9 methyl 2-((1r,4r)-4-(4-(1-(phenylcarbamoyl)-1H-indol-5-yl)phenyl)cyclohexyl)acetate 
• 1578241-60-7 methyl 2-((1r,4r)-4-(4-(4-(phenylcarbamoyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)phenyl)cyclohexyl)acetate 

Relevant academic research and scientific papers

Development of novel benzomorpholine class of diacylglycerol acyltransferase i inhibitors

Diacylglycerol acyltransferase 1 (DGAT1) presents itself as a potential therapeutic target for obesity and diabetes for its important role in triglyceride biosynthesis. Herein we report the rational design of a novel class of DGAT1 inhibitors featuring a

DERIVATIVES OF OXADIAZOLE AND PYRIDAZINE, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS

The invention relates to compounds of formula (I): in which: n is equal to 0 or 1; D represents an oxygen atom or a bond; W represents a nitrogen atom or a —CH— group; X1 represents a nitrogen atom or a —CH═CH— group; X2 represents an oxygen atom or a nitrogen atom; X3 represents an oxygen atom or a nitrogen atom; one of X1, X2, X3 being other than a nitrogen atom, X2 and X3 not being an oxygen atom at the same time; R1, R2 are absent or represent, (i) independently of one another, a hydrogen atom or a (C1-C4)alkyl group, (ii) R1 and R2 may form, with the carbon atom to which they are attached, a —(C3-C10)cycloalkyl- group; Y represents a —(C3-C10)cycloalkyl-, aryl or aryloxy group, said groups being optionally substituted with one or more substituents chosen from a halogen atom or a (C1-C6)alkoxy group; Z1 is absent or represents an —NH— function; Z2 and Z3 are as defined in the description. The invention also relates to a process for preparing compounds of formula (I), compositions containing them and their application in therapeutics.

Thiadiazoles as new inhibitors of diacylglycerol acyltransferase type 1

A novel class of DGAT1 inhibitors containing a thiadiazole core has been discovered. Chemical optimization lead to inhibitors of human DGAT1 with an appropriate ADME profile and that show in vivo activity in target tissues.